Document is current

Any future updates will be listed below

Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Crossref DOI link: https://doi.org/10.1186/s13046-022-02247-y

Published Online: 2022-01-27

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark